Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Corvus Pharmaceuticals Inc (CRVS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Corvus Pharmaceuticals's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.480 -0.030    -1.99%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.560
+0.080
+5.405%
19:22:59 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 64,871
  • Bid/Ask: 1.450 / 1.570
  • Day's Range: 1.410 - 1.520
Corvus Pharmaceuticals 1.480 -0.030 -1.99%

Corvus Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Corvus Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

28

Equity Type

ORD

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Contact Information

Address 863 Mitten Road Suite 102
Burlingame, 94010
United States
Phone 650 900 4520
Fax -

Top Executives

Name Age Since Title
Elisha P. Gould 64 2014 Independent Director
Richard A. Miller 70 2014 Co-Founder, President, CEO & Chairman of the Board
Peter A. Thompson 61 2014 Co-Founder & Independent Director
Scott W. Morrison 63 2015 Independent Director
Linda S. Grais 65 2019 Independent Director
Ian T. Clark 61 2017 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CRVS Comments

Write your thoughts about Corvus Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Jack Belforte
Jack Belforte Jun 06, 2023 6:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$3 $4 $5. $6 $7? CRVS ready to rumble?
Jack Belforte
Jack Belforte May 31, 2023 5:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
CRVS has a new following. Going to be a promising year.
My Itmail
My Itmail May 18, 2023 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
today 4.30 easy!!!! So buy at the opening
Pablo M.
Pablo M. Sep 30, 2021 12:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pablo M.
Pablo M. Sep 30, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pablo M.
Pablo M. Sep 30, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pablo M.
Pablo M. Sep 30, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pablo M.
Pablo M. Sep 30, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
tarbin kumar
tarbin kumar Sep 18, 2021 2:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
99% bull Monday morning
StockExchange NYbrokers
StockExchange NYbrokers Sep 18, 2021 2:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
@ do you think Tarbin will go down on Monday or more up ?
charles williams
charles williams Sep 18, 2021 12:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
might go down on Monday after 10-11am
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email